• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Battery-free, smart contact lens delivers glaucoma drugs

Article

Investigators from the Sun Yay-Sen University in Guangzhou have created a theranostic device that targets sensing rising fluid pressures within the eye to automatically deliver medication for a glaucoma patient.

Early testing of a smart contact lens shows promise for treating glaucoma, according to researchers in China.

  Investigators from the Sun Yay-Sen University in Guangzhou have created a theranostic device that targets sensing rising fluid pressures within the eye to automatically deliver medication for a glaucoma patient.

Investigators from the Sun Yay-Sen University in Guangzhou have created a theranostic device that targets sensing rising fluid pressures within the eye to automatically deliver medication for a glaucoma patient.

The wireless, double-layer contact lens measures intraocular pressure (IOP) by using small sensors—similar to that of a sandwich—that, when squeezed together, create an electrical signal.

When strong enough, the signal directly triggers the delivery of an anti-glaucoma drug. The drug is stored in a hydrogel layer that is within the lens and is delivered into the cornea with the aid of a weak electrical current.

The wireless, double-layer design of the contact lens creates a device that is minimally invasive, battery-free, and has the potential for large-scale production, as its manufacturing process is compatible with the commercial production of printed circuit boards, according to investigators.

The researchers recently published their findings in Nature Communications, where they reported results from testing the lens on the eyes of pigs and live rabbits.

In the rabbit experiment, the anti-glaucoma drug delivery lowered the IOP by about one-third within 30 minutes. It also helped to maintain those levels for a longer period of time when compared to delivery of the same drug via an eye drop (in which the IOP quickly bounced back).

Additional research is needed before clinical testing of the contact lens device can be done on human patients diagnosed with glaucoma.

According to researchers, the ideal device would consistently respond to fluctuations in an individual’s IOP before it ends up causing irreversible vision loss.

Related Videos
Marjorie Rah, OD, PhD, FAAO
Melissa Tawa, OD, FAAO
Deborah Ristvedt, DO, details CIME 2024 presentation on glaucoma management
Amy Butler of Bausch + Lomb details the company's recycling programs and initiatives for contact lenses and other eye care products
Neda Shamie, MD, details the upcoming CIME 2024 meeting
Charles Leclercq, CEO of ARxVision, details the new ARx AI headset and its uses
© 2024 MJH Life Sciences

All rights reserved.